24Business

Samsung Biologics Presents Business Update at JP Morgan Healthcare 2025 Conference By Investing.com

– The company will mark a new phase of growth in Bio Campus II with the opening of factory 5 in April

Samsung (KS:) Biologics offer ADC services and invest in advanced development and manufacturing capabilities to better meet client needs

INCHEON, South Korea, January 14, 2025 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business achievements and outlook for 2025 at the 43rd JP Morgan Healthcare Conferencence, which was held in San Francisco between January 13-16.

During the presentation of the main song, Samsung Biologics’ CEO and President John Rome said: “Despite industry challenges, Samsung Biologics is well positioned to launch a new phase of growth in 2025 with the opening of Bio Campus II and the launch of antibody-drug conjugate (ADC) services.” He added, “We will continue to invest in new modalities and technologies to better respond to client needs, maximizing satisfactionnor ensuring the delivery of the highest quality product.”

Key business news includes:

ADC services: To address the increasing demand for ADC-based therapy, Samsung Biologics has started ADC services in its new dedicated facility. Building on the company’s expertise in large-scale antibody production and process engineering, Samsung Biologics’ the scope of service includes late detection, development and conjugation. Samsung Biologics recently expanded his cooperationconversation with LigaChem Biosciences to support a range of their ADC programs at Samsung Biologics’ new dedicated ADC drive.

Opening Japan office: For better support Samsung Biologics’ expanding its global client base, the company announced plans to open a regional office in Tokyo this year. Local presence will increase Samsung Biologics ability to support and develop its growing partnerships in Japan.

Extended Medicine (DP) Services: As part of ongoing efforts to expand the range of services, Samsung Biologics invests in pre-filled syringe (PFS) capabilities. The company’s fully automated PFS DP line will be CGMP ready by 20207.

Improved development possibilities: Samsung Biologics plans to better support emerging global pharmaceutical and biotechnology companies by investing in core development capabilities. The company offers services that include new technology platforms, including S-HiConS-TensifyS-AfuCHOand S-OptiChargewhich ensure higher productivity and quality of the molecule for successful and accelerated drug development.

Capacity expansion: Samsung Biologics will mark a new phase of growth with the opening of Bio Campus II this year. Plant 5, the first plant at the new location, will be commissioned in April this year and will increase the total capacity to 784,000 liters. The company is also considering the construction of a sixth plant to proactively respond to the growing demand for biologics, which will increase the total production capacity to 964,000 liters upon board approval.

Digital transformation: As part of an effort to maximize operational efficiency and customer satisfaction, Samsung Biologics will continue to invest in the further construction of its integrated digital systems covering quality, production and operations. Incorporating artificial intelligence and digital twin technology, the company plans to provide clients with solutions enabled by data and insight to optimize project timelines without compromising quality.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic filling/finishing as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are CGMP compliant with bioreactors ranging from small to large to meet diverse client needs. Maximizing operational efficiency and expanding our capabilities in response to growing demand for biomanufacturing, Samsung Biologics offers a total capacity of 604 kL in Bio Campus I. The company launched Bio Campus II with the construction of plant 5, which will be operational in April 2025, adding 180 kL of bio-production capacity. In addition, Samsung Biologics America allows the company to work in close proximity to clients based in the OUR and Europe. We continue to build our capabilities to meet our customers by investing in an ADC facility, mRNA technologies and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to the timely and complete delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence and proven expertise.

Contact Samsung Biologics
Claire Kimleader Global marketing communications
cair.kim@samsung.com





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Social Media Auto Publish Powered By : XYZScripts.com